Resilience is the first-of-its-kind biopharmaceutical manufacturer which claims to revolutionize the future of medicine by creating novel medicines for the better protection of mankind. The company provides a platform to the finest brains around the world and facilitates them with every technology and approach to carry out extensive research and devise novel therapies and vaccines like never before!
The companies make wise investments in the development of powerful and innovative manufacturing technologies across various therapeutics interventions like vaccines, proteins, viral vectors, and most importantly cell and gene therapies. These investments are accredited to the brilliant team of executives, advisors, and board of directors running the whole show! They have unparalleled levels of experience in the biopharmaceutical industry, an impeccable academic background, and a mind-blowing business skill set. All of them are striving hard to make sure that all the patients can access important medicines whenever they need them while protecting against the disruption in the supply chain.
Robert Nelson, the founder and Chairman of the Board, states that Resilience was created to explore biopharmaceutical manufacturing via extraordinary investment in technology. The company is an effort to combat the critical vulnerabilities in medical supply chains that have affected scientific innovation and medical discovery. Thus, the team is determined to produce and distribute critically important drugs, facilitating everybody in need.
Resilience aims to address today’s issues while also investing in the future of biopharmaceutical innovation in the United States. It aims to provide tailored and scalable processes, quick lead times, industry-leading assurance and broader strategy, and global manufacturing facilities. Pharmaceutical and biotechnology businesses, institutions of higher education, autonomous research organizations, and administration programs will all benefit from it. Like Amazon Web Services, the company aims to provide drug developers with the tools they need. These tools will help them better synchronize discovery, development, and manufacturing, as well as new chances to engross in downstream novelties and manufacturing breakthroughs even if products are still being created.
What is even more interesting is that Resilience enables partners to focus on developing discoveries that enhance medical outcomes and save patients’ lives by enabling complicated drug manufacturing that is more rapid, supple, and less hazardous. The company has reportedly raised 800 million dollars in capital, despite a brief Series B financing of around $750 million from investors who jointly oversee over $5 trillion. Investors included public mutual funds, some of the top U.S. based pharmaceutical corporations, foundations, family offices, and pension funds, among others, led by ARCH Venture Partners and 8VC with support from GV and NEA.
Resilience is home to certified experts from various fields. For instance, biopharmaceutical industry, drug research, and manufacturing, artificial intelligence, machine learning, cyber security, software development, etc. Owing to such rich diversity, Resilience can absolutely be the biopharmaceutical manufacturer to revolutionize the future of medicine, right?
For further information and assistance, you can visit their official website; resilience.com.
